Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora.

Trial Profile

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Bacterial infections; Infectious conjunctivitis
  • Focus Pharmacodynamics
  • Sponsors Alcon
  • Most Recent Events

    • 01 Jun 2012 Actual end date Jun 2007 added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual patient number (137) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Investigational drug changed from trimethoprim/polymixin B to moxifloxacin as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top